Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
A child who suffers a moderate or severe traumatic brain injury (TBI) may still have substantial functional disabilities and reduced quality of life 2 years after the injury. After those first 2 years, further improvement may be minimal. Better interventions are needed to prevent long-lasting consequences of TBI in children conclude the authors of a study published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Professor Yvonne Perrie, Chair in Drug Delivery at Aston University, Birmingham UK has won the prestigious Royal Pharmaceutical Society's Pharmaceutical Scientist of the Year Award for her contribution to developing a new tuberculosis vaccine.
A novel set of custom-designed "molecular beacons" allows scientists to monitor gene expression in living populations of stem cells as they turn into a specific tissue in real-time. The technology, which Brown University researchers describe in a new study, provides tissue engineers with a potentially powerful tool to discover what it may take to make stem cells transform into desired tissue cells more often and more quickly.
Rhode Island Hospital's Center of Biomedical Research Excellence (COBRE) in Skeletal Health and Repair has been awarded a $10.8 million grant from the National Institutes of Health (NIH), one of the largest grants in Rhode Island Hospital history. This grant, to be paid over five years, will fund studies of cartilage and joint health.
A team of experts in mechanics, materials science, and tissue engineering at Harvard have created an extremely stretchy and tough gel that may pave the way to replacing damaged cartilage in human joints.
Sigma-Aldrich Corporation today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure. The Reconstructed Skin Micronucleus (RSMN) Assay represents the first commercial offering of a Genetic Toxicology assay using three-dimensional tissue models.
Some of the body's own genetic material, known as small interfering RNA (siRNA), can be packaged then unleashed as a precise and persistent technology to guide cell behavior, researchers at Case Western Reserve University report in the current issue of the journal, Acta Biomaterialia.
BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.
For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.
Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.
Biologists, surgical oncologists and regenerative medicine specialists from Rice University, the University of Delaware and the Christiana Care Health System in Wilmington, Del., have begun a four-year program aimed at using cells to grow whole salivary glands that can replace those destroyed by cancer radiation therapy.
University of Delaware professor Xinqiao Jia is part of a research team breaking new ground in the creation of artificial salivary glands.
A National Cheng Kung University research team has made a breakthrough in the regeneration of new blood vessels in cardiovascular therapy by using nanofibers and vascular endothelial growth factor.
For more than 1 million people in the U.S. living with spinal cord injury, the frightening days and weeks following the injury are filled with uncertainty about their potential for recovery and future independence. A new model based on motor scores at admission and early imaging studies may allow clinicians to predict functional outcomes and guide decision-making for therapy and care-giving needs, as described in an article published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.
Study findings suggest that burn wound eschar-derived mesenchymal cells represent a population of multipotent stem cells, which could be a new resource for engineering approaches to heal burn wounds.
University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.
Researchers at the Royal College of Surgeons in Ireland (RCSI) have developed a new method of repairing bone using synthetic bone graft substitute material, which combined with gene therapy, can mimic real bone tissue and has potential to regenerate bone in patients who have lost large areas of bone from either disease or trauma.
Seventeen National Institutes of Health grants are aimed at creating 3-D chips with living cells and tissues that accurately model the structure and function of human organs such as the lung, liver and heart. Once developed, these tissue chips will be tested with compounds known to be safe or toxic in humans to help identify the most reliable drug safety signals - ultimately advancing research to help predict the safety of potential drugs in a faster, more cost-effective way.
Using recent advances in marine biomechanics, materials science, and tissue engineering, a team of researchers at Harvard University and the California Institute of Technology (Caltech) have turned inanimate silicone and living cardiac muscle cells into a freely swimming "jellyfish."
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.